Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 2/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519449 | 0.93 | ALDH1A1 (0.53) | ALDH1A1TSHRPRKCAPRKCDCTSK | |
| SCHEMBL15520525 | 0.90 | TSHR (0.47) | ALDH1A1TSHRPRKCAPRKCDCTSK | |
| SCHEMBL5889388 | 0.89 | ALDH1A1 (0.57) | ALDH1A1TSHRCTSKCTSLCTSB | |
| SCHEMBL819755 | 0.89 | TSHR (0.46) | ALDH1A1TSHRPRKCAPRKCDCTSK | |
| SCHEMBL3183024 | 0.87 | TSHR (0.47) | ALDH1A1TSHRPRKCAPRKCDCTSK | |
| SCHEMBL28667562 | 0.85 | ALDH1A1 (0.46) | ALDH1A1TSHRCTSK | |
| SCHEMBL2297614 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHR | |
| SCHEMBL1984781 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHR | |
| SCHEMBL540819 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHR | |
| SCHEMBL1924504 | 0.81 | TSHR (0.49) | ALDH1A1TSHRCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104704-A1 | A COMBINATION, MEDICAL KIT AND MEDICAL DEVICE FOR TREATING AND/OR PREVENTING TISSUE LEAKAGE | FUNDACIÓ INSTITUT DE INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL (ES) | 2026-05-21 | — | — | WO | claimed |
| EP-4744687-A1 | A COMBINATION, MEDICAL KIT AND MEDICAL DEVICE FOR TREATING AND/OR PREVENTING TISSUE LEAKAGE | Aesculap AG (DE) | 2026-05-20 | — | — | EP | claimed |
| US-20230138395-A1 | PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE | BIOSERGEN AS (NO) | 2023-05-04 | — | — | US | claimed |
| EP-4110305-A1 | PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE | Biosergen AS (NO) | 2023-01-04 | — | — | EP | claimed |
| WO-2026104704-A1 | A COMBINATION, MEDICAL KIT AND MEDICAL DEVICE FOR TREATING AND/OR PREVENTING TISSUE LEAKAGE | FUNDACIÓ INSTITUT DE INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL (ES) | 2026-05-21 | — | — | WO | disclosed |
| EP-4744687-A1 | A COMBINATION, MEDICAL KIT AND MEDICAL DEVICE FOR TREATING AND/OR PREVENTING TISSUE LEAKAGE | Aesculap AG (DE) | 2026-05-20 | — | — | EP | disclosed |
| US-20250339579-A1 | SURGICAL THREAD, SURGICAL SUTURE AND SURGICAL KIT | B BRAUN SURGICAL SA (ES) | 2025-11-06 | — | — | US | disclosed |
| EP-4531939-A1 | SURGICAL THREAD, SURGICAL SUTURE AND SURGICAL KIT | B. Braun Surgical, S.A. (ES) | 2025-04-09 | — | — | EP | disclosed |
| CN-112584824-B | Nanoparticles | 新泰福托特股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023233011-A1 | SURGICAL THREAD, SURGICAL SUTURE AND SURGICAL KIT | B. BRAUN SURGICAL S.A. (ES) | 2023-12-07 | — | — | WO | disclosed |
| EP-4285946-A1 | SURGICAL THREAD, SURGICAL SUTURE AND SURGICAL KIT | B. Braun Surgical, S. A. (ES) | 2023-12-06 | — | — | EP | disclosed |
| US-20230138395-A1 | PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE | BIOSERGEN AS (NO) | 2023-05-04 | — | — | US | disclosed |
| EP-4110305-A1 | PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE | Biosergen AS (NO) | 2023-01-04 | — | — | EP | disclosed |
| CN-113840594-A | Poly (alkyl cyanoacrylate) nanoparticles for the treatment of cancer | 新泰福托特股份有限公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-112584824-A | Nanoparticles | 新泰福托特股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| EP-2708245-B1 | COMPOSITION, REACTION PRODUCT, KIT AND APPLICATOR, ESPECIALLY FOR USE IN MEDICINE | AESCULAP AG (DE) | 2019-03-20 | — | — | EP | disclosed |
| EP-2708245-A2 | Composition, reaction product, kit and applicator, especially for use in medicine | AESCULAP AG (DE) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138395-A1 | PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE | CEL, LIPA, HDAC6 | ALDH1A1 4396/4885TSHR 4097/4885PRKCA 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.